LyGenesis Entered into a Joint Research Collaboration with Imagine Pharma to Develop Novel Cell Therapies for Type 1 Diabetes
Shots:
- The companies collaborated to develop novel cell therapies for patients with type 1 diabetes using Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis' allogeneic cell therapy platform
- The partnership will facilitate the rapid development of a preclinical proof of concept program for type 1 diabetes treatment using Imagine Pharma's AIPCs as the cell source with LyGenesis' use of the lymph node as a bioreactor to grow a functioning ectopic pancreas
- LyGenesis' lead allogeneic cell therapy program is currently in a P-IIa clinical trial for the treatment of patients with end-stage liver disease
Ref: PR Newswire | Image: LyGenesis
Related News:- Luxna Entered into a Collaboration Agreement with Servier for Drug Discovery Research to Treat Neurological Diseases
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
